These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34371534)

  • 1. [Chinese multidisciplinary expert consensus on combined immunotherapy based on immune checkpoint inhibitors for hepatocellular carcinoma(2021 version)].
    ; ;
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):636-647. PubMed ID: 34371534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunotherapy clinical application and research prospects for liver cancer].
    Xia F; Chen XP
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):615-617. PubMed ID: 34371529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chinese multidisciplinary expert consensus on combined immunotherapy for hepatocellular carcinoma(2023 version)].
    ; ;
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jan; 31(1):16-34. PubMed ID: 36948846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition).
    Liu X; Lu Y; Zhou W; Peng T; Zhou J; Bi H; Xia F; Chen X
    Liver Cancer; 2024 Aug; 13(4):355-375. PubMed ID: 39114757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
    Yin X; Wu T; Lan Y; Yang W
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35075482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus.
    Liu L; Xiang Z; Li Y; Guo W; Yang K; Wang J; Sun Z; Ren G; Zhang J; Sun M; Ran W; Huang G; Tang Z; Li L
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2022 Dec; 40(6):619-628. PubMed ID: 36416313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immune checkpoint inhibitors in the treatment and management of hepatocellular carcinoma-related adverse reactions].
    Li ZC; Ren ZG
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):600-603. PubMed ID: 34225439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.
    Greten TF; Abou-Alfa GK; Cheng AL; Duffy AG; El-Khoueiry AB; Finn RS; Galle PR; Goyal L; He AR; Kaseb AO; Kelley RK; Lencioni R; Lujambio A; Mabry Hrones D; Pinato DJ; Sangro B; Troisi RI; Wilson Woods A; Yau T; Zhu AX; Melero I
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver.
    Hewitt DB; Rahnemai-Azar AA; Pawlik TM
    Expert Opin Investig Drugs; 2021 Aug; 30(8):827-835. PubMed ID: 34102935
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation.
    Peeraphatdit TB; Wang J; Odenwald MA; Hu S; Hart J; Charlton MR
    Hepatology; 2020 Jul; 72(1):315-329. PubMed ID: 32167613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).
    Yang Y; Sun J; Wu M; Lau WY; Zheng S; Wang XH; Chen X; Fan J; Dong J; Cai J; Chen M; Chen Y; Cheng Z; Dai C; Shan J; Du CY; Fang C; Hu H; Ji Z; Jia W; Li G; Li J; Li J; Liu C; Liu F; Ma Y; Mao Y; Niu Z; Shen J; Shi J; Shi X; Song W; Sun HC; Tan G; Tao R; Wang X; Wen T; Wu L; Xia J; Xiang BD; Yan M; Ying M; Zhang L; Zhang X; Zeng ZC; Zhang Y; Zhang Z; Zhou J; Zhou C; Zhou J; Zhou L; Zhou X; Zhu J; Zhu Z; Zhang Q; Li Q; Cheng S
    Liver Cancer; 2022 Dec; 11(6):511-526. PubMed ID: 36589726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.
    Wang Y; Jiang M; Zhu J; Qu J; Qin K; Zhao D; Wang L; Dong L; Zhang X
    Biomed Pharmacother; 2020 Dec; 132():110797. PubMed ID: 33068935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy-Based Treatments of Hepatocellular Carcinoma:
    Cannella R; Lewis S; da Fonseca L; Ronot M; Rimola J
    AJR Am J Roentgenol; 2022 Oct; 219(4):533-546. PubMed ID: 35506555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chinese expert consensus on intra-arterial drug and combined drug administration for primary hepatocellular carcinoma].
    Specialist Group of Interventional Drugs, Interventionalists Branch of Chinese Medical Doctor Association
    Zhonghua Nei Ke Za Zhi; 2023 Jul; 62(7):785-801. PubMed ID: 37394848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expert consensus on assessing tumor response to immune checkpoint inhibitors by PET/CT (2020 Edition)].
    PET Group, Chinese Society of Nuclear Medicine
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):697-705. PubMed ID: 32988149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
    Guardascione M; Toffoli G
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor.
    Wang W; Wang Q; Xu C; Li Z; Song Z; Zhang Y; Cai X; Zhang S; Lian B; Li W; Liu A; Zhan P; Liu H; Lv T; Miao L; Min L; Chen Y; Yuan J; Wang F; Jiang Z; Lin G; Pu X; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Xie C; Zhang J; Guo H; Chu Q; Meng R; Wu J; Zhang R; Wang L; Zhu Y; Hu X; Xie Y; Lin X; Cai J; Lan F; Feng H; Wang L; Yao W; Shi X; Huang J; Chen H; Zhang Y; Sun P; Wan B; Pang F; Xu Z; Wang K; Xia Y; Ye M; Wang D; Wei Q; Feng S; Zhou J; Zhang J; Lv D; Gao W; Kang J; Yu G; Liang X; Yu C; Shi L; Yang N; Wu L; Hong Z; Hong W; Fang M; Zhang Y; Lu Y; Wang G; Ma S; Si L; Fang W; Song Y
    Thorac Cancer; 2022 Dec; 13(23):3420-3430. PubMed ID: 36268845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice.
    Pinter M; Scheiner B; Pinato DJ
    Lancet Gastroenterol Hepatol; 2023 Aug; 8(8):760-770. PubMed ID: 37327807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma.
    Lee BM; Seong J
    World J Gastroenterol; 2021 Mar; 27(10):919-927. PubMed ID: 33776363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
    Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
    Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.